The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family:Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions

Advances in Pharmacology

Volumn 44, Issue C, 1998, Pages 225-342

  Houslap, Miles D ^a   Sullivan, Michael ^b   Bolgerz, Graeme B ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV;

AMINO ACID SEQUENCE; ANIMAL; DEPRESSION; ENZYMOLOGY; GENETICS; HUMAN; INFLAMMATION; MOLECULAR GENETICS; PHYSIOLOGY; REVIEW; SEQUENCE ALIGNMENT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; SEQUENCE ALIGNMENT;

EID: 0031601339     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60128-3     Document Type: Chapter

References (279)

1. Akaike N., Uneyama H., Kawa K., and Yamshita Y. Existence of rolipram-sensitive phosphodiesterase in rat megakaryocyte. Br. J. Pharmacol. 109 (1993) 1020-1023
2. AlAlaiyan S., AlOmran A., and Dyer D. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Intensive Care Med. 22 (1996) 1093-1095
3. Alvarez R., Sette C., Yang D., Eglen R.M., Wilhelm R., Shelton E.R., and Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48 (1995) 616-622
4. Ashton M.J., Cook D.C., Fenton G., Karlsson J.A., Palfreyman M.N., Raeburn D., Ratcliffe A.J., Souness J.E., Thurairatnam S., and Vicker N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem. 37 (1994) 1696-1703
5. Atz A.M., Adatia I., and Wessel D.L. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann. Thorac. Surg. 62 (1996) 1759-1764
6. Averill L.E., Stein R., and Kammer G.M. Control of human T lymphocyte interleukin 2 production by a cAMP-dependent pathway. Cell. Immunol. 115 (1988) 88-99
7. Baecker P.A., Obernolte R., Bach C., Yee C., and Shelton E.R. Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD). Gene 138 (1994) 253-256
8. Banner K.H., and Page C.P. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur. Respir. J. 8 (1995) 996-1000
9. Banner K.H., Roberts N.M., and Page C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br. J. Pharmacol. 116 (1995) 3169-3174
10. Barnard J.W., Seibert A.F., Prasad V.R., Smart D.A., Strada S.J., Taylor A.E., and Thompson W.J. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. J. Appl. Physiol. 77 (1994) 774-781
11. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., and Torphy T.J. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 273 (1995) 1396-1402
12. Barnette M.S., Manning C.D., Cieslinski L.B., Burman M., Christensen S.B., and Torphy T.J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther. 273 (1995) 674-679
13. Barnette M.S., Oleary Bartus J., Burman M., Christensen S.B., Cieslinski L.B., Esser K.M., Prabhakar U.S., Rush J.A., and Torphy T.J. Association of the antiinflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. 51 (1996) 949-956
14. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
15. Beavo J.A., Conti M., and Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46 (1994) 399-405
16. Beavo J.A., and Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11 (1990) 150-155
17. Benovic J.L., DeBlasi A., Stone W.C., Caron M.G., and Lefkowitz R.J. Betaadrenergic receptor kinase: Primary structure delineates a multigene family. Science 246 (1989) 235-240
18. Birnbaumer L., Abramowitz J., and Brown A.M. Receptor-effector coupling by G proteins. Biochim. Biophys. Acta 1031 (1990) 163-224
19. Bloom T.J., and Beavo J.A. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93 (1996) 14188-14192
20. Bolger G. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cell. Signal. 6 (1994) 851-859
21. Bolger G., Michaeli T., Martins T., St John T., Steiner B., Rodgers L., Riggs M., Wigler M., and Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol. Cell. Biol. 13 (1993) 6558-6571
22. Bolger G.B., Erdogan S., Jones R.E., Loughney K., Wilkinson I., Farrell C., and Houslay M.D. Characterisation of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328 (1997) 539-548
23. Bolger G.B., McPhee I., and Houslay M.D. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J. Biol. Chem. 271 (1996) 1065-1071
24. Bolger G.B., Rodgers L., and Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149 (1994) 237-244
25. Booker G.W., Gout I., Downing A.K., Driscoll P.C., Boyd J., Waterfield M.D., and Campbell I.D. Solution structure and ligand-binding site of the SH3 domain of the p85alpha subunit of phosphatidylinositol 3-kinase. Cell 73 (1993) 813-822
26. Byers D., Davis R.L., and Kiger J.A. Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophila. Nature 289 (1981) 79-83
27. Cannizzaro G., Gagliano M., La Rocca S., Novara V., and Flugy A. Evaluation of alprazolam-induced behavioural effects: Differences with chlordiazepoxide after interaction with desipramine and rolipram, a cAMP phosphodiesterase inhibitor. Pharmacol. Res. 21 Suppl. 5 (1989) 53-54
28. Cavalla D., and Frith R. Phosphodiesterase IV inhibitors: Structural diversity and therapeutic potential in asthma. Curr. Med. Chem. 2 (1995) 561-572
29. Chan S.C., Li S.H., and Hanifin J.M. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J. Invest. Dermatol. 100 (1993) 681-684
30. Chan S.C., Reifsnyder D., Beavo J.A., and Hanifin J.M. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J. Allergy Clin. Immunol. 91 (1993) 1179-1188
31. Charbonneau H. Structure-function relationships among cyclic nucleotide phosphodiesterases. In: Beavo J., and Houslay M.D. (Eds). Cyclic Nucleotide Phosphodiesterases (1990), John Wiley, Chichester. 2267-2298
32. Chen C.N., Denome S., and Davis R.L. Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce + gene, the structural gene for cAMP phosphodiesterase. Proc. Nat. Acad. Sci. USA 83 (1986) 9313-9317
33. Cheng J.B., Cooper K., Duplantier A.J., Eggler J.F., Kraus K.G., Marshall S.C., Marfat A., Masamune H., Shirley J.T., Tickner J.E., and Umland J.P. Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site. Bioorg. Med. Chem. Lett. 5 (1995) 1969-1972
34. Cohan V.L., Showell H.J., Fisher D.A., Pazoles C.J., Watson J.W., Turner C.R., and Cheng J.B. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J. Pharmacol. Exp. Ther. 278 (1996) 1356-1361
35. Colicelli J., Birchmeir C., Michaeli T., O'Neill K., Riggs M., and Wigler M. Isolation and characterisation of a mammalian gene encoding a high affinity cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 86 (1989) 3599-3603
36. Colicelli J., Nicolette C., Birchmeier C., Rodgers L., Riggs M., and Wigler M. Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 88 (1991) 2913-2917
37. Conti M., lona S., Cuomo M., Swinnen J.V., Odeh J., and Svoboda M.E. Characterization of a hormone-inducible, high affinity adenosine 3'-5'-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry 34 (1995) 7979-7987
38. Conti M., Jin S.L.C., Monaco L., Repaske D.R., and Swinnen J.V. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endoc. Rev. 12 (1991) 218-234
39. Conti M., Nemoz G., Sette C., and Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endoc. Rev. 16 (1995) 370-389
40. Dauwalder B., and Davis R.L. Conditional rescue of the dunce learning/memory and female fertility defects with Drosophila or rat transgenes. J. Neurosci. 15 (1995) 3490-3499
41. Davis R.L. Mutational analysis of phosphodiesterase in Drosophila. Methods Enzymol. 159 (1988) 786-792
42. Davis R.L. Physiology and biochemistry of Drosophila learning mutants. Physiol. Rev. 76 (1996) 299-317
43. Davis R.L., and Davidson N. The memory gene dunce+ encodes a remarkable set of RNAs with internal heterogeneity. Mol. Cell. Biol. 6 (1986) 1464-1470
44. Davis R.L., Takayasu H., Eberwine M., and Myres J. Cloningand characterisation of mammalian homologs of the Drosophila dunce+ gene. Proc. Natl. Acad. Sci. USA 86 (1989) 3604-3608
45. de Boer J., Philpott A., van Amsterdam R.G., Shahid M., Zaagsma J., and Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106 (1992) 1028-1034
46. De Mendez I., Adams A.G., Sokolic R.A., Malech H.L., and Leto T.L. Multiple SH3 domain interactions regulate NADPH oxidase assembly in whole cells. EMBO J. 15 (1996) 1211-1220
47. Dent G., and Giembycz M.A. Selective phosphodiesterase inhibitors in the therapy of asthma. Clin, lmmunother. 3 (1995) 423-437
48. Dent G., Giembycz M.A., Rabe K.F., and Barnes P.J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103 (1991) 1339-1346
49. DiSanto M.E., and Heaslip R.J. Rolipram inhibition of phosphodiesterase-4 activation. Eur. J. Pharmacol. 290 (1995) 169-172
50. Dudai Y., Jan Y.N., Byers D., Quinn W.G., and Benzer S. Dunce, a mutant of Drosophila deficient in learning. Proc. Natl. Acad. Sci. USA 73 (1976) 1684-1688
51. Duplantier A.J., Biggers M.S., Chambers R.J., Cheng J.B., Cooper K., Damon D.B., Eggler J.F., Kraus K.G., Marfat A., Masamune H., Pillar J.S., Shirley J.T., Umland J.P., and Watson J.W. Biarylcarboxylic acids and amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39 (1996) 120-125
52. Eckmann F., Fichte K., Meya U., and Sastre-Y-Hernandez M. Rolipram in major depression: Results of a double-blind comparative study with amitriptyline. Curr. Ther. Res. 43 (1988) 291-295
53. Eker P., Holm P.K., Van Deurs B., and Sandvig K. Selective regulation of apical endocytosis in polarized Madin-Darby canine kidney cells by mastoparan and cAMP. J. Biol. Chem. 269 (1994) 18607-18615
54. Engels P., AbdelAl S., Hulley P., and Lubbert H. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J. Neurosci. Res. 41 (1995) 169-178
55. Engels P., Fichtel K., and Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350 (1994) 291-295
56. Engels P., Sullivan M., Muller T., and Lubbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 358 (1995) 305-310
57. Erdogan S., and Houslay M.D. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits a net increase in cyclic AMP phosphodiesterase activity by upregulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as downregulating a novel PDE4A splice variant. Biochem. J. 271 (1997) 165-175
58. Essayan D.M., Huang S.K., KageySobotka A., and Lichtenstein L.M. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99 (1997) 28-37
59. Faux M.C., and Scott J.D. Molecular glue: Kinase anchoring and scaffold proteins. Cell 85 (1996) 9-12
60. Faux M.C., and Scott J.D. More on target with protein phosphorylation: Conferring specificity by location. Trends Biochem. Sci. 21 (1996) 312-318
61. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., and Simhandl C. A multicenter double-blind study of three different doses of the new cAMP- phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26 (1992) 59-64
62. Fonteh A.N., Winkler J.D., Torphy T.J., Heravi J., Undem B.J., and Chilton F.H. Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J. Immunol. 151 (1993) 339-350
63. Francis S.H., Colbran J.L., Mc AllisterLucas L.M., and Corbin J.D. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 269 (1994) 22477-22480
64. Francis S.H., Noblett B.D., Todd B.W., Wells J.N., and Corbin J.D. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol. Pharmacol. 34 (1988) 506-517
65. Fullerton D.A., Hahn A.R., Banerjee A., and Harken A.H. Pulmonary vascular smooth muscle relaxation by cGMP- versus cAMP-mediated mechanisms. J. Surg. Res. 57 (1994) 259-263
66. Giembycz M.A. Phosphodiesterase 4 and tolerance to beta2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci. 17 (1996) 331-336
67. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., and Barnes P.J. Identification of cyclic AMP phosphodiesterases3, 4 and 7 in human CD4+ and CD8+ T-lymphocy tes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118 (1996) 1945-1958
68. Greten T.F., Eigler A., Sinha B., Moeller J., and Endres S. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. Int. J. Immunopharmacol. 17 (1995) 605-610
69. Guruprasad L., Dhanaraj V., Timm D., Blundell T.L., Gout I., and Waterfield M.D. The crystal structure of the N-terminal SH3 domain of Grb2. J. Mol. Biol. 248 (1995) 856-866
70. Hallsworth M.P., Giembycz M.A., Barnes P.J., and Lee T.H. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br. J. Pharmacol. 117 (1996) 79-86
71. Hanifen J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson W.R., Kirby D.S., and Weiner E.S. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiinflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107 (1996) 51-56
72. Harris A.L., Connell M.J., Ferguson E.W., Wallace A.M., Gordon R.J., Pagani E.D., and Silver P.J. Role of low K(m) cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Exp. Ther. 251 (1989) 199-206
73. Hatzelmann A., Tenor H., and Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol. 114 (1995) 821-831
74. Hatzelmann A., Tenor H., and Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol. 114 (1995) 821-831
75. Hebenstreit G.F., Fellerer K., Fichte K., Fischer G., Geyer N., and Meya U. Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22 (1989) 156-160
76. Hempel C.M., Vincent P., Adams S.R., Tsien R.Y., and Selverston A.I. Spatiotemporal dynamics of cyclic AMP signals in an intact neural circuit. Nature 384 (1996) 166-169
77. Henkel-Tigges J., and Davies R.L. Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and Ro-20-1724. Mol. Pharmacol. 37 (1990) 7-10
78. Heyworth C.M., Grey A.-M., Wilson S.R., Hanski E., and Houslay M.D. The action of islet activating protein (pertussis toxin) in insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. Biochem. J. 235 (1986) 145-149
79. Heyworth C.M., Rawal S., and Houslay M.D. Guanine nucleotides can activate the insulin-stimulated phosphodiesterase in liver plasma membranes. FEBS Lett. 154 (1983) 87-91
80. Heyworth C.M., Wallace A.V., and Houslay M.D. Insulin and glucagon regulate the activation of two distinct membrane-bound cyclic AMP phosphodiesterases in hepatocytes. Biochem. J. 214 (1983) 99-110
81. Heyworth C.M., Wallace A.V., Wilson S.R., and Houslay M.D. An assessment of the ability of insulin-stimulated cyclic AMP phosphodiesterase to decrease hepatocyte intracellular cyclic AMP concentrations. Biochem. J. 222 (1984) 183-187
82. Heyworth C.M., Wilson S.P., Gawler D.J., and Houslay M.D. The phorbol ester TPA prevents the expression of both glucagon desensitisation and the glucagon-mediated block of insulin stimulation of the peripheral plasma membrane cyclic AMP phosphodiesterase in rat hepatocytes. FEBS Lett. 187 (1985) 196-200
83. Hichami A., Boichot E., Germain N., Berdyshev E., Coqueret O., and Lagente V. Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors. Mediators Inflamm. 5 (1996) 425-428
84. Hoffmann R., Wilkinson I., McCallum F.R., Engels P., and Houslay M.D. Regulation of human cyclic AMP specific phosphodiesterase PDE4D3 by phosphorylation and substitution at ser54. (1998) Submitted.
85. Horton Y.M., Sullivan M., and Houslay M.D. Correction: Molecular cloning of a novel splice variant of human type 1V(A) (PDE-IV(A)) cyclic AMP phosphodiesterase and localization of the gene to the pl3. 1-ql2 region of human chromosome 19. Biochem. J. (1995) 683-691
86. Biochem. J. 312 (1995) 991
87. Horton Y.M., Sullivan M., and Houslay M.D. Molecular cloning of a novel splice variant of human type IV(A) (PDE-IV(A)) cyclic AMP phosphodiesterase and localization of the gene to the pi 3. 1-ql2 region of human chromosome 19. Biochem. J. 308 (1995) 683-691
88. Houslay M.D. Insulin, glucagon and the receptor-mediated control of cyclic AMP concentrations in liver. Biochem. Soc. Trans. 14 (1986) 183-193
89. Houslay M.D. The use of selective inhibitors and computer modelling to evaluate the role of specific high affinity cyclic AMP phosphodiesterases in the hormonal regulation of hepatocyte intracellular cyclic AMP concentrations. Cell. Signal. 2 (1990) 85-98
90. Houslay M.D. 'Crosstalk': A pivotal role for protein kinase C in modulating relationships between signal transduction pathways. Eur. J. Biochem. 195 (1991) 9-27
91. Houslay M.D. G-protein linked receptors: A family probed by molecular cloning and mutagenesis procedures. Clin. Endocrinol. 36 (1992) 525-534
92. Houslay M.D. Protein kinase C and the modulation of G-protein controller adenylyl cyclase and other signal transmission systems. In: Sibley D., and Houslay M.D. (Eds). In Desensitization in Molecular Pharmacology of Cell Regulation (1994), John Wiley, Chichester. 3129-3168
93. Houslay M.D. The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. Biochem. Soc. Trans. 24 (1996) 980-986
94. Houslay M.D., and Kilgour E. In: Beavo J.A., and Houslay M.D. (Eds). Cyclic Nucleotide Phosphodiesterases (1990), John Wiley, Chichester. 2185-2226
95. Houslay M.D., and Marchmont R.J. The insulin-stimulated cyclic AMP phosphodiesterase binds to a single class of protein sites on the liver plasma membrane. Biochem. J. 198 (1981) 703-706
96. Houslay M.D., and Milligan G. Tailoring cAMP signalling responses through isoform multiplicity. Trends Biochem. 22 (1997) 217-224
97. Houslay M.D., Needham L., Dodd N.J.F., and Grey A.M. Acidic phospholipid species inhibit adenylate cyclase activity in rat liver plasma membranes. Biochem. J. 235 (1986) 237-243
98. Houslay M.D., Scotland G., Pooley L., Spence S., Wilkinson I., McCallum F., Julien P., Rena N.G., Michie A.M., Erdogan S., Zeng L., O'Connell J.C., Tobias E.S., and MacPhee I. Alternative splicing of the type-IVA cyclic AMP phosphodiesterase gene provides isoform variants with distinct N-terminal domains fused to a common, soluble catalytic unit: 'Designer' changes in V(max.), stability and membrane association. Biochem. Soc. Trans. 23 (1995) 393-398
99. Houslay M.D., and Tipton K.F. A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem. J. 139 (1974) 645-652
100. Howell R.E., Jenkins L.P., Fielding L.E., and Grimes D. Inhibition of antigen induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm. Pharmacol. 8 (1995) 83-89
101. Howell R.E., Jenkins L.P., and Howell D.E. Inhibition of lipopolysaccharide induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. J. Pharmacol. Exp. Ther. 275 (1995) 703-709
102. Hughes B., Hewat D., Lisle H., Holbrook M., James T., Gozzard N., Blease K., Hughes P., Kingaby R., Warrellow G., Alexander R., Head J., Boyd E., Eaton M., Perry M., Wales M., Smith B., Owens R., Higgs G., et al. The inhibition of antigen induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118 (1996) 1183-1191
103. Hulley P., Hartikka J., Abdel'Al S., Engels P., Buerki H.R., Weiderhold K.H., Muller T., Kelly P., Lowe D., and Lubbert H. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. 7 (1995) 2431-2440
104. Huston E., Lumb S., Russell A., Catterall C., Ross A.H., Steele M.R., Bolger G.B., Perry M., Owens R., and Houslay M.D. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cyclic AMP specific phosphodiesterase, HSPDE4B3. Biochem. J. 328 (1997) 549-558
105. Huston E., Pooley L., Julien J., Scotland G., McPhee I., Sullivan M., Bolger G., and Houslay M.D. The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species which exhibit distinct kinetics of inhibition by the anti-depressant rolipram. J. Biol. Chem. 271 (1996) 31334-31344
106. Ichimura M., and Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193 (1993) 985-990
107. Imanishi T., Sawa A., Ichimaru Y., Miyashiro M., Kato S., Yamamoto T., and Ueki S. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur. J. Pharmacol. 321 (1997) 273-278
108. Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shetton E.R., and Conti M. Characterisation of the rolipram sensitive cAMP-specific phosphodiesterases in rat brain. Mol. Pharmacol. (1998) (in press.)
109. Jacobitz S., McLaughlin M.M., Livi G.P., Burman M., and Torphy T.J. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 50 (1996) 891-899
110. Jacobitz S., Ryan M.D., McLaughlin M.M., Livi G.P., DeWolf W.E., and Torphy T.J. Role of conserved histidines in catalytic activity and inhibitor binding of recombinant phosphodiesterase 4A. Mol. Pharmacol. 50 (1997) 891-899
111. Jin S.L.C., Swinnen J.V., and Conti M. Characterization of the structure of a low K(m), rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J. Biol. Chem. 267 (1992) 18929-18939
112. Kambayashi T., Jacob C.O., Zhou D., Mazurek N., Fong M., and Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155 (1995) 4909-4916
113. Kaminuma O., Hikkawa H., Matsubara S., and Ikezawa K. Effect of a novel phosphodiesterase IV inhibitor, T-440, on antigen- and chemical mediator-induced bronchoconstrictions in guinea pigs in vivo. Jpn. J. Pharmacol. 72 (1996) 1-8
114. Kaminuma O., Mori A., Suko M., Nishizaki Y., Kikkawa H., Ikezawa K., and Okudaira H. A novel phosphodiesterase inhibitor, T-440: Possible management of eosinophilic inflammation by down-regulation of interleukin-5 production. Int. Arch. Allergy Immunol. 111 (1996) 16-18
115. Kaneko T., Alvarez R., Ueki I.F., and Nadel J.A. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7 (1995) 527-534
116. Kelly J.J., Barnes P.J., and Giembycz M.A. Phosphodiesterase 4 in macrophages: Relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. Biochem. J. 318 (1996) 425-436
117. Kilgour E., Anderson N.G., and Houslay M.D. Activation of the 'dense-vesicle' cyclic AMP-phosphodiesterase from rat liver by cyclic AMP-dependent protein kinase. Biochem. Soc. Trans. 16 (1988) 1025-1026
118. Kilgour E., Anderson N.G., and Houslay M.D. Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase. Biochem. J. 260 (1989) 27-36
119. Klauck T.M., and Scott J.D. The postsynaptic density: A subcellular anchor for signal transduction enzymes. Cell. Signal. 7,7 (1995) 47-757
120. Kochetkova M., Burns F.M.F., and Souness J.E. Isoprenaline induction of cAMP phosphodiesterase in guinea pig macrophages occurs in the presence, but not in the absence, of phosphodiesterase type IV inhibitor rolipram. Biochem. Pharmacol. 50 (1995) 2033-2038
121. Kovala T., Lorimer I.A., Brickenden A.M., Ball E.H., and Sanwal B.D. Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts. J. Biol. Chem. 269 (1994) 8680-8685
122. Krause D.S., and Deutsch C. Cyclic AMP directly inhibits IL-2 receptor expression in human T-cells. J. Immunol. 146 (1991) 2285-2294
123. Krause W., Kuhne G., and Sauerbrey N. Pharmacokinetics of (+)-rolipram and (-)- rolipram in healthy volunteers. Eur. J. Clin. Pharmacol. 38 (1990) 71-75
124. Lagente V., Moodley I., Perrin S., Mottin G., and Junien J.L. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 255 (1994) 253-256
125. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., and Vallar L. GTPase inhibiting mutations activate the alpha chain of G(s) and stimulate adenylyl cyclase in human pituitary tumours. Nature 340 (1989) 692-696
126. Lavan B.E., Lakey T., and Houslay M.D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem. Pharmacol. 38 (1989) 4123-4136
127. Lenhard J.M., Kassel D.B., Rocque W.J., Hamacher L., Holmes W.D., Patel I., Hoffman C., and Luther M. Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. Biochem. J. 316 (1996) 751-758
128. Lingk D.S., Chan M.A., and Gelfand E.W. Increased cyclic adenosine monophosphate levels block progression but not initiation of human T cell proliferation. J. Immunol. 145 (1990) 449-455
129. Livi G.P., Kmetz P., McHale M.M., Cieslinski L.B., Sathe G.M., Taylor D.P., Davis R.L., Torphy T.J., and Balcarek J.M. Cloning and expression of cDNA for a human low-K(m), rolipram-sensitive cyclic AMP phosphodiesterase. Mol. Cell. Biol. 10 (1990) 2678-2686
130. Lobban M., Shakur Y., Beattie J., and Houslay M.D. Identification of two splice variant forms of type-IV(B) cyclic AMP phosphodiesterase, DPD (rPDE-IV(Bl)) and PDE-4 (rPDE-IV(B2)) in brain: Selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304 (1994) 399-406
131. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochem. Biophys. Acta 1179 (1993) 171-188
132. Londesborough J. Evidence that the peripheral cyclic AMP phosphodiesterase of rat liver plasma membranes is a metalloenzyme. Biochem. J. 225 (1985) 143-147
133. Lowe J.A., and Cheng J.B. The PDEIV family of calcium independent phosphodiesterase enzymes. Drugs Future 17 (1992) 799-807
134. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.Y., Clark O.H., Kawasaki E., Bourne H.R., and McCormick F. Two G protein oncogenes in human endocrine tumors. Science 249 (1990) 655-659
135. Macphee C.H., Reifsnyder D.H., Moore T.A., and Beavo J.A. Intact cell and cell-free phosphorylation and concomitant activation of a low K(m), cAMP phosphodiesterase found in human platelets. J. Cyclic Nucleotide Protein Phosphor. Res. 11 (1986) 487-496
136. Madelian V., and La Vigne E. Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Biochem. Pharmacol. 51 (1996) 1739-1747
137. Manganiello V.C., Murata T., Taira M., Belfrage P., and Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322 (1995) 1-13
138. Manganiello V.C., Taira M., Degerman E., and Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE 3 gene family). Cell. Signal. 7 (1995) 445-455
139. Manning C.D., McLaughlin M.M., Livi G.P., Cieslinski L.B., Torphy T.J., and Barnette M.S. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. Mol. Pharmacol. 276 (1996) 810-818
140. Marchmont R.J., Ayad S.R., and Houslay M.D. Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. Biochem. J. 195 (1981) 645-652
141. Marchmont R.J., and Houslay M.D. Insulin triggers cyclic AMP-dependent activation and phosphorylation of a plasma membrane cyclic AMP phosphodiesterase. Nature 286 (1980) 904-906
142. Marchmont R.J., and Houslay M.D. An intrinsic and a peripheral protein constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187 (1980) 381-392
143. Marchmont R.J., and Houslay M.D. Characterization of the phosphorylated form of the insulin-stimulated cyclic AMP phosphodiesterase rat liver plasma membranes. Biochem. J. 195 (1981) 653-660
144. Marcoz P., Nemoz G., Prigent A.F., and Lagarde M. Phosphatidic acid stimulates the rolipram-sensitive PDE4 from thymocytes. Biochim. Biophys. Acta 1176 (1993) 129-136
145. Masamune H., Cheng J.B., Cooper K., Eggler F., Marfat A., Marsh S.C., Shirley J.T., Tickner J.E., Umland J.P., and Vazquez E. Discovery of micromolar PDE IV inhibitors that exhibit much reduced affinity for the [3H]rolipram binding site: 3-norbornyloxy-4-methoxyphenylmethylene oxindoles. Bioorg. Med. Chem. Lett. 5 (1995) 1965-1968
146. McAllister-Lucas L.M., Sonnenburg W.K., Kadlecek A., Seger D., Hai Le T., Colbran J.L., Thomas M.K., Walsh K.A., Francis S.H., Corbin J.D., and Beavo J.A. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. 268 (1993) 22863-22873
147. McHale M.M., Cieslinski L.B., Eng W.K., Johnson R.K., Torphy T.J., and Livi G.P. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast. Mol. Pharmacol. 39 (1991) 109-113
148. McLaughlin M.M., Cieslinski L.B., Burman M., Torphy T.J., and Livi G.P. A low-K(m), rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J. Biol. Chem. 268 (1993) 6470-6476
149. McPhee I., Pooley L., Lobban M., Bolger G., and Houslay M.D. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310 (1995) 965-974
150. McPhee I., Yarwood S., Houslay E.S., Scotland G., and Houslay M.D. Identification of a conformational trigger region in the cAMP specific phosphodiesterase HSPDE4A which is operated through SH3 domain interaction. (1998) (Submitted).
151. Merilainen J., Palovuori R., Sormunen R., Wasenius V., and Lehto V. Binding of the alpha-fodrin SH3 domain to the leading lamellae of locomoting chicken fibroblasts. J. Cell Sci. 105 (1993) 647-654
152. Michaeli T., Bloom T.J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J.A., and Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268 (1993) 12925-12932
153. Michie A.M., Lobban M., Muller T., Harnett M.M., and Houslay M.D. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T-cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell. Signal. 8 (1996) 97-110
154. Milatovich A., Bolger G., Michaeli T., and Francke U. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat. Cell Mol. Genet. 20 (1994) 75-86
155. Monaco L., Vicini E., and Conti M. Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J. Biol. Chem. 269 (1994) 347-357
156. Morena A.R., Boitani C., De Grossi S., Stefanini M., and Conti M. Erratum: Stage and cell-specific expression of the adenosine 3',5'-monophosphate-phosphodiesterase genes in the rat seminiferous epithelium (Endocrinology [1995] 136, 687-695). Endocrinology 136 (1995) 1558
157. Morena A.R., Boitani C., De Grossi S., Stefanini M., and Conti M. Stage and cell-specific expression of the adenosine 3',5'-monophosphate-phosphodiesterase genes in the rat seminiferous epithelium. Endocrinology 136 (1995) 687-695
158. Muller T., Engels P., and Fozard J.R. Sub types of the type 4cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol. Sci. 17 (1996) 294-298
159. Mumby M.C., Martins T.J., Chang M.L., and Beavo J.A. Identification of cGMP-stimulated cyclic nucleotide phosphodiesterase in lung tissue with monoclonal antibodies. J. Biol. Chem. 257 (1982) 13283-13290
160. Nakashima S., Mizutani T., Nakamura Y., Takemura S.O., Nakamura M., Miyata H., Katagiri Y., and Nozawa Y. Effects of selective phosphodiesterase type IV inhibitor, rolipram, on signal transducing phospholipases in neutrophil: Inhibition of phospholipases A2, D but not C. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 112 (1995) 137-143
161. Nemoz G., Prigent A.-F., Moueqqit M., Fougier S., Mascovschi O., and Pacheco H. Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brains by the neurotropic compound rolipram. Biochem. Pharmacol. 34 (1985) 2997-3000
162. Nemoz G., Sette C., and Conti M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol. Pharmacol. 51 (1997) 242-249
163. Nemoz G., Sette C., Hess M., Muca C., Vallar L., and Conti M. Activation of cyclic nucleotide phosphodiesterases in FRTL-5 thyroid cells expressing a constitutively active Gsalpha. Mol. Endocrinol. 9 (1995) 1279-1287
164. Nemoz G., Zhang B., Sette C., and Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 384 (1996) 97-102
165. Newsholme S.J., and Schwartz L. cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. Inflammation 17 (1993) 25-31
166. Nicholson C.D., Challiss R.A.J., and Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12 (1991) 19-27
167. Nicholson C.D., and Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-Their potential utility in the therapy of asthma. Pulm. Pharmacol. 7 (1994) 1-17
168. Nielson C.P., Vestal R.E., Sturm R.J., and Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86 (1990) 801-808
169. Nighorn A., Healy M.J., and Davis R.L. The cyclic AMP phosphodiesterase encoded by the Drosophila dunce gene is concentrated in the mushroom body neuropil. Neuron 6 (1991) 455-467
170. Noel P.E., Fletcher J.R., and Thompson W.J. Rolipram and isoproterenol reverse platelet activating factor-induced increases in pulmonary microvascular permeability and vascular resistance. J. Surg. Res. 59 (1995) 159-164
171. O'Connell J.C., McCallum J., FäMcPhee I., Wakefield J., Houslay E.S., Wishart W., Bolger G., Frame M., and Houslay M.D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cyclic AMP specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem. J. 318 (1996) 255-262
172. Obernolte R., Bhakta S., Alvarez R., Bach C., Zuppan P., Mulkins M., Jarnagin K., and Shelton E.R. The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 129 (1993) 239-247
173. Obernolte R., Ratzliff J., Daniels D.V., Zuppan P., Jarnagin K., and Shelton E.R. Multiple splice variants of phosphodiesterase PDE4C from human lung and testis. Biochim. Biophys. Acta. (1997) In press.
174. Omburo G.A., Torphy T.J., Scott G., Jacobitz S., Colman R.F., and Colman R.W. Inactivation of recombinant monocyte cAMP-specific phosphodiesterase by camp analog, 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic monophosphate. Blood 89 (1997) 1019-1026
175. Ottonello L., Morone M.P., Dapino P., and Dallegri F. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol. 101 (1995) 502-506
176. Owens R.J., Catterall C., Batty D., Jappy J., Russell A., Smith B., O'Connell J., and Perry M. Human phosphodiesterase 4A: Characterization of full length and truncated enzymes expressed in COS cells. Biochem. J. 326 (1997) 53-60
177. Owens R.J., Lumb S., Rees-Mikon K., Russell A., Baldock D., Lang V., Crabbe T., Ballesteros M., and Perry M.J. Cell. Signal. 9 (1997) 575-586
178. Palfreyman M.N. Phosphodiesterase type IV inhibitors as antiinflammatory agents. Drugs Future 20 (1995) 793-804
179. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., and Poison J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48 (1994) 827-835
180. Pawson T., and Gish G.D. SH2 and SH3 domains: From structure to function. Cell 71 (1992) 359-362
181. Peachell P.T., Undem B.J., Schleimer R.P., MacGlashan Jr. D.W., Lichtenstein L.M., Cieslinski L.B., and Torphy T.J. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148 (1992) 2503-2510
182. Pillai R., Kytle K., Reyes A., and Colicelli J. Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Proc. Natl. Acad. Sci. USA 90 (1993) 11970-11974
183. Pillai R., Staub S.F., and Colicelli J. Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J. Biol. Chem. 269 (1994) 30676-30681
184. Polson J.B., and Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 403-427
185. Ponting C.P. Novel domains in NADPH oxidase subunits, sorting nexins, and Ptdlns 3-kinases: Binding partners of SH3 domains?. Protein Sci. 5 (1996) 2353-2357
186. Pooley L., Shakur Y., Rena G., and Houslay M.D. Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in transfected human thyroid carcinoma FTC cell lines. Biochem. J. 271 (1997) 177-185
187. Price B., Pyne N.J., and Houslay M.D. Proteolysis of cAMP phosphodiesterase-III attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue. Biochem. Pharmacol. 36 (1987) 4047-4054
188. Pyne N.J., Anderson N., Lavan B.E., Milligan G., Nimmo H.G., and Houslay M.D. Specific antibodies and the selective inhibitor ICI 118233 demonstrates that the hormonally-stimulated 'dense-vesicle' and peripheral plasma membrane cyclic AMP phosphodiesterase display distinct tissue distribution in the rat. Biochem. J. 248 (1987) 897-901
189. Pyne N.J., Cooper M.E., and Houslay M.D. Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. Biochem. J. 234 (1986) 325-334
190. Pyne N.J., Cooper M.E., and Houslay M.D. The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem. J. 242 (1987) 33-42
191. Pyne N.J., Cushley W., Nimmo H.G., and Houslay M.D. Insulin stimulates the tyrosyl phosphorylation and activation of the 52 kDa peripheral plasma-membrane cyclic AMP phosphodiesterase in intact hepatocytes. Biochem. J. 261 (1989) 897-904
192. Pyne N.J., Stevens R., and Houslay M.D. Proteolysis of the 52kDa insulin-activated peripheral plasma membrane cAMP phosphodiesterase. Biochem. Soc. Trans. 17 (1989) 666-667
193. Qiu Y., Chen C.N., Malone T., Richter L., Beckendorf S.K., and Davis R.L. Characterization of the memory gene dunce of Drosophila melanogaster. J. Mol. Biol. 211 (1991) 553-565
194. Qiu Y., and Davis R.L. Genetic dissection of the learning/memory gene dunce of Drosophila melanogaster. Genes Dev. 7 (1993) 1447-1458
195. Rabe K., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266 (1994) L536-L543
196. Rabe K.F., Tenor H., Dent G., Schudt C., Liebig S., and Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am. J. Physiol. 264 (1993) L458-L464
197. Raeburn D., and Advenier C. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: Effects on airways smooth muscle. Int. J. Biochem. Cell Biol. 27 (1995) 29-37
198. Raeburn D., and Karlsson J.A. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo. J. Pharmacol. Exp. Ther. 267 (1993) 1147-1152
199. Raeburn D., Souness J.E., Tomkinson A., and Karlsson J.A. Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: Biochemistry, pharmacology and therapeutic potential in asthma. Prog. Drug Res. 40 (1993) 9-32
200. Raeburn D., Underwood S.L., Lewis S.A., Woodman V.R., Battram C.H., and Tomkinson A. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br. J. Pharmacol. 113 (1994) 1423-1431
201. Reeves M.L., Leigh B.K., and England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochetn. J. 241 (1987) 535-541
202. Ricard J., Meunier J.C., and Buc J. A mnemonical enzyme mechanism. Eur. J. Biochem. 49 (1974) 195-208
203. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., and Poison J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42 (1991) 869-877
204. Rosenmund C., Carr D.W., Bergeson S.E., Nilaver G., Scott J.D., and Westbrook G.L. Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons. Nature 368 (1994) 853-856
205. Rubin C.S. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim. Biophys. Acta 1224 (1994) 467-479
206. Savany A., Abriat C., Nemoz G., Lagarde M., and Prigent A.F. Activation of a cyclic nucleotide phosphodiesterase 4 (PDE4) from rat thymocytes by phosphatidic acid. Cell. Signal. 8 (1996) 511-516
207. Schmiechen R., Schneider H.H., and Wachtel H. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology 102 (1990) 17-20
208. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. Pharmacol. 127 (1986) 105-115
209. Schudt C., Tenor H., and Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8 (1995) 1179-1183
210. Schwabe U., Miyake M., Ohga Y., and Daly J.W. 4-(-3-cyclopentyloxy-4-methoxy)-2-pyrrolidone (ZK 62711): A potent inhibitor of adenosine cyclic 3'5'-mono-phosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol. Pharmacol. 12 (1976) 900-910
211. Scotland G., and Houslay M.D. Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IV(Al)) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyl-transferase. Biochem. J. 308 (1995) 673-681
212. Scott A.I., Perini A.F., Shering P.A., and Whalley L.J. In-patient major depression: Is rolipram as effective as amitriptyline?. Eur. J. Clin. Pharmacol. 40 (1991) 127-129
213. Scott J.D. Cyclic nucleotide-dependent protein kinases. Pharmacol. Ther. 50 (1991) 123-145
214. Sette C., and Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271 (1996) 16526-16534
215. Sette C., Iona S., and Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269 (1994) 9245-9252
216. Sette C., Vicini E., and Conti M. Modulation of cellular responses by hormones: Role of cAMP specific, rolipram-sensitive phosphodiesterases. Mol. Cell. Endocrinol. 100 (1994) 75-79
217. Sette C., Vicini E., and Conti M. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269 (1994) 18271-18274
218. Shabb J.B., and Corbin J.D. Cyclic nucleotide-binding domains in proteins having diverse functions. J. Biol. Chem. 267 (1992) 5723-5726
219. Shakur Y., Pryde J.G., and Houslay M.D. Engineered deletion of the unique N-terminal domain in the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem. J. 292 (1993) 677-686
220. Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S.L., Campbell A.M., Beattie J., Daly C., and Houslay M.D. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306 (1995) 801-809
221. Smith K.J., Scotland G., Beattie J., Trayer I.P., and Houslay M.D. Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructs. J. Biol. Chem. 271 (1996) 16703-16711
222. Souness J.E., Carter C.M., Diocee B.K., Hassall G.A., Wood L.J., and Turner N.C. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem. Pharmacol. 42 (1991) 937-945
223. Souness J.E., Griffin M., Maslen C., Ebsworth K., Scott L.C., Pollock K., Palfreyman M.N., and Karlsson J.A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFalpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 118 (1996) 649-658
224. Souness J.E., Hassall G.A., and Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44 (1992) 857-866
225. Souness J.E., Maslen C., and Scott L.C. Effects of solubilization and vanadate/ glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett. 302 (1992) 181-184
226. Souness J.E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M.N., Ashton M.J., and Karlsson J.A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram. Br. J. Pharmacol. 115 (1995) 39-46
227. Souness J.E., and Rao S. Proposal for pharmacologically distinct conformers of PDE4. Cell. Signal. 9 (1997) In press.
228. Souness J.E., and Scott L.C. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J. 291 (1993) 389-395
229. Souness J.E., Villamil M.E., Scott L.C., Tomkinson A., Giembycz M.A., and Raeburn D. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br. J. Pharmacol. 111 (1994) 1081-1088
230. Sparks A.B., Rider J.E., Fowlkes D.M., Quilliam L.A., and Kay B.K. Distinct preferences of src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLC-γ, Crk and Grb2. Proc. Natl. Acad. Sci. USA 93 (1996) 1540-1544
231. Sullivan M., Egerton M., Shakur Y., Marquardson A., and Houslay M.D. Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IV (A), cyclic AMP specific phosphosiesterase (hPDE(A-h6.1)). Cell. Signal. 6 (1994) 793-812
232. M. Sullivan, S. Erdogan, M. Wilson, M.D. Houslay (1998a). Generation of an active chimeric cyclic AMP phosphodiesterase, HYB1 by replacement of the C-terminal domain of the inactive human PDE4A splice variant 2EL (HSPDE4A7). Submitted.
233. M. Sullivan, G. Rena, L. Gordon, A.S. Olsen, M.D. Houslay, (1998b). Molecular cloning and characterisation of the human PDE4A cyclic AMP specific gene locus and mapping to chromosome 19pl3.2. Submitted.
234. Sunahara R.K., Dessauer C.W., and Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 461-480
235. Suttorp N., Ehreiser P., Hippenstiel S., Fuhrmann M., Krull M., and Tenor H. Hyperpermeability of pulmonary endothelial monolayer: Protective role of phosphodiesterase isoenzymes 3 and 4. Lung 174 (1996) 181-194
236. Swinnen J.V., Dsouza B., Conti M., and Ascoli M. Attenuation of cAMP-mediated responses in MA-10 Leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase. J. Biol. Chem. 266 (1991) 14383-14389
237. Swinnen J.V., Joseph D.R., and Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: Evidence for a family of genes. Proc. Natl. Acad. Sci. USA 86 (1989) 5325-5329
238. Swinnen J.V., Tsikalas K.E., and Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266 (1991) 18370-18377
239. Szpirer C., Szpirer J., Riviere M., Swinnen J., Vicini E., and Conti M. Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP specific phosphodiesterases 3 and 4. Cytogenet. Cell Genet. 69 (1995) 11-14
240. Takayama H., Trenn G., and Sitkovsky M.V. Locus of inhibitory action of cAMP- dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J. Biol. Chem. 263 (1988) 2330-2336
241. Takeda S., Lin C.T., Morgano P.G., Mclntyre S.J., and Dousa T.P. High activity of low Michaelis-Menten constant 3'5' cAMP phosphodiesterase isoenzymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus. Endocrinology 129 (1991) 287-294
242. Takemoto D.J., Hansen J., Takemoto L.J., and Houslay M.D. Peptide mapping of the multiple forms of cyclic nucleotide phosphodiesterase. J. Biol. Chem. 257 (1982) 14597-14599
243. Tang E.K.Y., and Houslay M.D. Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity. Biochem. j. 283 (1992) 341-346
244. Teixeira M.M., Rossi A.G., Giembycz M.A., and Hellewell P.G. Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation. Br. J. Pharmacol. 118 (1996) 2099-2106
245. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanovic R., and Schudt C. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25 (1995) 625-633
246. Tetsuka T., Kusano E., Takeda S., Homma S., Yoshida I., Ando Y., and Asano Y. Activation of protein kinase C stimulates cAMP phosphodiesterase in rat renal collecting tubules. Am. J. Physiol. 268 (1995) F808-F814
247. Thompson W.J. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol. Ther. 51 (1991) 13-33
248. Thompson W.J., Epstein P.M., and Strada S.J. Purification and characterization of high-affinity cyclic adenosine monophosphate phosphodiesterase from dog kidney. Biochemistry 18 (1979) 5228-5237
249. Thompson W.J., Tan B.H., and Strada S.J. Activation of rabbit liver high affinity cAMP (type IV) phosphodiesterase by a vanadyl-glutathione complex. Characterization of the role of the sulfhydryl. J. Biol. Chem. 266 (1991) 17011-17019
250. Thusu K.G., Morin F.C.H.I., Russell J.A., and Steinhorn R.H. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am. J. Respir. Crit. Care Med. 152 (1995) 1605-1610
251. Torphy T.J. Biochemical regulation of airway smooth muscle tone: Current knowledge and therapeutic implications. Rev. Clin. Basic Pharmacol. 6 (1987) 61-103
252. Torphy T.J. Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: Challenges to the dogma. Trends Pharmacol. Sci. 15 (1994) 370-374
253. Torphy T.J., Barnette M.S., Hay D.W.P., and Underwood D.C. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ. Health Perspect. 102 (1994) 79-84
254. Torphy T.J., Dewolf W., Green D.W., and Livi G.P. Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions 43 (1993) 51-71
255. Torphy T.J., Livi G.P., and Christensen S.B. Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect. 6 (1993) 203-214
256. Torphy T.J., Stadel J.M., Burman M., Cieslinski L.B., McLaughlin M.M., White J.R., and Livi G.P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 267 (1992) 1798-1804
257. Torphy T.J., and Undem B.J. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 46 (1991) 512-523
258. Torphy T.J., Undem B.J., Cieslinski L.B., Luttmann M.A., Reeves M.L., and Hay D.W.P. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 265 (1993) 1213-1223
259. Torphy T.J., Zhou H.L., Foley J.J., Sarau H.M., Manning C.D., and Barnette M.S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J. Biol. Chem. 270 (1995) 23598-23604
260. Undem B.J., Torphy T.J., Goldman D., and Chilton F.H. Inhibition by adenosine 3':5'-monophosphate of eicosanoid and platelet-activating factor biosynthesis in the mouse PT-18 mast cell. J. Biol. Chem. 265 (1990) 6750-6758
261. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W.P., and Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270 (1994) 250-259
262. Underwood D.C., Osborn R.R., Novak L.B., Matthews J.K., Newsholme S.J., Undem B.J., Hand J.M., and Torphy T.J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266 (1993) 306-313
263. Verghese M.W., McConnell R.T., Lenhard J.M., Hamacher L., and Jin S.-L.C. Regulation of distinct cyclic AMP-specific phosphodiesterase (PDE4) isozymes in human monocytic cells. Mol. Pharmacol. 47 (1995) 1164-1171
264. Vicini E., and Conti M. Characterization of an intronic promoter of a cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol. Endocrinol. 11 (1997) 839-850
265. Wacholtz M.C., Minakuchi R., and Lipsky P.E. Characterization of the 3',5'-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cell. Immunol. 135 (1991) 285-298
266. Wachtel H. Characteristic behavioural alterations in rats induced by rolipram and other selective cyclic AMP phosphodiesterase inhibitors. Psychopharmacology 77 (1982) 309-314
267. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3'5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22 (1983) 267-272
268. Wagner U., Bredenbroker D., Fehmann H.C., Schwarz F., Schudt C., and Von Wichert P. Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat. Eur. J. Pharmacol. 298 (1996) 265-270
269. Wallace A.V., Heyworth C.M., and Houslay M.D. N6-(Phenylisopropyl) adenosine prevents glucagon both blocking insulin's activation of the plasma-membrane cyclic AMP phosphodiesterase and uncoupling hormonal stimulation of adenylate cyclase activity in hepatocytes. Biochem. J. 222 (1984) 177-182
270. Wilkinson I., Enhels P., and Houslay M.D. Rolipram inhibition of the human cyclic AMP specific phosphodiesterase splice variant PDE4D3 expressed in yeast (S cerevisiae). Pharmacol Revs. Commun. 9 (1997) 215-226
271. Willette R.N., Shiloh A.O., Sauermelch C.F., Sulpizio A., Michell M.P., Cieslinski L.B., Torphy T.J., and Ohlstein E.H. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors. J. Cereb. Blood Flow Metab. 17 (1997) 210-219
272. Wilson M., Sullivan M., Brown N., and Houslay M.D. Purification, characterization and analysis of rolipram inhibition of a human type-IV(A) cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem. J. 304 (1994) 407-415
273. Woodford T.A., Correll L.A., McKnight G.S., and Corbin J.D. Expression and characterization of mutant forms of the type I regulatory subunit of cAMP-dependent protein kinase. The effect of defective cAMP binding on holoenzyme activation. J. Biol. Chem. 264 (1989) 13321-13328
274. Wright C.D., Kuipers P.J., Kobylarz Singer D., Devall L.J., Klinkefus B.A., and Weishaar R.E. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 40 (1990) 699-707
275. Wu H., and Parsons J. Cortactin, an 80/85-kilodalton pp60(src) substrate, is a filamentous actin-binding protein enriched in the cell cortex. J. Cell Biol. 120 (1993) 1417-1426
276. Yamaki M., Mclntyre S., Murphy J.M., Swinnen J.V., Conti M., and Dousa T.P. ADH resistance of LLC-PK1 cells caused by overexpression of cAMP-phosphodiesterase type-IV. Kidney Int. 43 (1993) 1286-1297
277. Ye Y., and Odonnell J.M. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J. Neurochem. 66 (1996) 1894-1902
278. Zhong Y., and Wu C.F. Altered synaptic plasticity in Drosophila memory mutants with a defective cyclic AMP cascade. Science 251 (1991) 198-201
279. Ziegler J.W., Ivy D.D., Fox J.J., Kinsella J.P., Clarke W.R., and Abman S.H. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am. J. Physiology 269 (1995) H473-H479